Pregnancy outcome after exposure to antidepressants and the role of maternal depression: Results from the Norwegian mother and child cohort study

Journal of Clinical Psychopharmacology

Volumn 32, Issue 2, 2012, Pages 186-194

  Nordeng, Hedvig ^a,b   Van Gelder, Marleen M H J ^c   Spigset, Olav ^d,e   Koren, Gideon ^f   Einarson, Adrienne ^f   Eberhard Gran, Malin ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Antidepressants; Birth defects; Low birth weight; Pregnancy; Preterm birth

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; BIRTH WEIGHT; COHORT ANALYSIS; CONGENITAL MALFORMATION; DEPRESSION; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; INFANT; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; NORWAY; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; SOCIAL STATUS;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIRTH WEIGHT; COHORT STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; INFANT, NEWBORN; NORWAY; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PREMATURE BIRTH; PROSPECTIVE STUDIES; QUESTIONNAIRES; REGISTRIES; RISK; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84857872157     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182490eaf     Document Type: Article

References (64)

1. Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004;103(4):698-709. (Pubitemid 40459031)
2. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008;198(2):194.e1- 194.e5.
3. Bakker MK, Kö lling P, van den Berg PB, et al. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol. 2008;65(4):600-606. (Pubitemid 351365128)
4. Ramos E, Oraichi D, Rey E, et al. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG. 2007;114(9):1055-1064. (Pubitemid 47247022)
5. Engeland A, Bramness JG, Daltveit AK, et al. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol. 2008;65(5):653-660.
6. Bakker MK, Kerstjens-Frederikse WS, Buys CH, et al. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol. 2010;88(2):94-100.
7. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009;339:b3569.
8. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol. 2008;66(5):695-705.
9. Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356(26):2684-2692. (Pubitemid 47001036)
10. Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16(10):1075-1085. (Pubitemid 350020060)
11. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356(26):2675-2683. (Pubitemid 47001035)
12. Wogelius P, Norgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology. 2006;17(6):701-704. (Pubitemid 44655607)
13. Wichman CL, Moore KM, Lang TR, et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc. 2009;84(1):23-27.
14. Einarson A, Choi J, Einarson TR, et al. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry. 2009;54(4):242-246.
15. Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf. 2007;16(10):1086-1094. (Pubitemid 350020061)
16. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005;106(6):1289-1296. (Pubitemid 41668948)
17. Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol. 2003;188(3):812-815. (Pubitemid 36332456)
18. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159(12):2055-2061. (Pubitemid 35423865)
19. Ericson A, Källén B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol. 1999;55(7):503-508. (Pubitemid 29446550)
20. Chambers C, Johnson K, Dick L, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335(14):1010-1015. (Pubitemid 26338730)
21. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279(8):609-610. (Pubitemid 28110208)
22. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993;269(17):2246-2248. (Pubitemid 23120281)
23. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010;40(10):1723-1733.
24. Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. 2010;88(3):159-170.
25. Bérard A. Paroxetine exposure during pregnancy and the risk of cardiac malformations: what is the evidence? Birth Defects Res A Clin Mol Teratol 2010;88(3):171-174
26. Scialli AR. Paroxetine exposure during pregnancy and cardiac malformations. Birth Defects Res AClin Mol Teratol. 2010;88(3):175-177.
27. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf. 2005;14(12):823-827. (Pubitemid 43056107)
28. Malm H, Artama M, Gissler M, et al. Selective serotonin reuptake inhibitors and risk for major congenital anomalies [published online ahead of print]. Obstet Gynecol. 2011;118(1):111-120.
29. Colvin L, Slack-Smith L, Stanley FJ, et al. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol. 2011;91(3):142-152.
30. Einarson A, Choi J, Einarson TR, et al. Adverse effects of antidepressant use in pregnancy: an evaluation of fetal growth and preterm birth. Depress Anxiety. 2010;27(1):35-38.
31. Nakhai-Pour HR, Broy P, Bérard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ. 2010;182(10):1031-1037.
32. Toh S, Mitchell AA, Louik C, et al. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol. 2009;29(6):555-560.
33. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med. 2009;163(10):949-954.
34. Suri R, Altshuler L, Hellemann G, et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry. 2007;164(8):1206-1213. (Pubitemid 47292409)
35. Lennestål R, Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 2007;27(6):607-613. (Pubitemid 351339448)
36. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63(8):898-906. (Pubitemid 44188483)
37. Grote NK, Bridge JA, Gavin AR, et al. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010;67(10):1012-1024.
38. Norwegian Institute of Public Health. The Norwegian Mother and Child Cohort Study. Oslo, Norway: Norwegian Institute of Public Health; 2010. Available at: http://www.fhi.no/eway/?pid=233; http://www.fhi.no/eway/default. aspx?pid=238&trg=MainArea-5811&MainArea-5811=5903:0:15,4329:1:0:0:::0:0. Accessed May 5, 2010.
39. Magnus P, Irgens LM, Haug K, et al. Cohort profile: the Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol. 2006;35(5):1146-1150. (Pubitemid 44605528)
40. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years. Acta Obstet Gynecol Scand. 2000;79(6):435-439. (Pubitemid 30326123)
41. WHO Collaborating Centre for Drugs Statistics Methodology. ATC/DDD index 2010. Available at: http://www.whocc.no/atc-ddd-index/. Accessed February 24, 2010.
42. World Health Organization. International Statistical Classification of Disease and Related Health Problems, 10th Revision. Available at: http://apps.who.int/classifications/apps/icd/icd10online/. Accessed May 5, 2010.
43. Norwegian Institute of Public Health. Medical Birth Registry of Norway. Oslo, Norway: Norwegian Institute of Public Health; 2010. Available at: http://www.fhi.no/eway/?pid=233; http://www.fhi.no/eway/default.aspx?pid= 238&trg=MainArea-5811&MainArea-5811=5895:0:15,3320:1:0:0:::0: 0&MainLeft-5895=5825:73560::1:5896:4:::0:0. Accessed May 5, 2010.
44. Strand BH, Dalgard OS, Tambs K, et al. Measuring the mental health status of the Norwegian population: a comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). Nord J Psychiatry. 2003;57(2):113-118. (Pubitemid 36626132)
45. Fink P, Orbol E, Hansen MS, et al. Detecting mental disorders in general hospitals by the SCL-8 scale. J Psychosom Res. 2004;56(3):371-375. (Pubitemid 38445089)
46. Fink P, Ornbol E, Huyse FJ, et al. A brief diagnostic screening instrument for mental disturbances in general medical wards. J Psychosom Res. 2004;57(1):17-24. (Pubitemid 38906666)
47. Hesbacher P, Rickets R, Morris R, et al. Psychiatric illness in family practice. J Clin Psychiatry. 1980;41(1):6-10. (Pubitemid 10132548)
48. Winikur A,Winikur D, Rickets K, et al. Symptoms of emotional distress in a family planning service: stability over a four-week period. Br J Psychiatry. 1984;144:395-399.
49. Sandanger I, Moum T, Ingebrigtsen GH, et al. Concordance between symptom screening and diagnostic procedure. The Hopkins Symptom Checklist-25 and the Composite International Diagnostic Interview I. Soc Psychiatry Psychiatr Epidemiol. 1998;33(7):345-354.
50. Nettelbladt P, Hansson LC, Stefansson G. Test characteristics of the Hopkins Symptom Check List-25 (HSCL-25) in Sweden, using the Present State Examination (PSE-9) as a caseness criterion. Soc Psychiatry Psychiatr Epidemiol. 1993;28(3):130-133. (Pubitemid 23256549)
51. Tambs K, Moum T. How well can a few questionnaire items indicate anxiety and depression? Acta Psychiatr Scand. 1993;87(5):364-367. (Pubitemid 23134648)
52. Predictive Analytics SoftWare (PASW) Statistics 18.0. Chicago, IL: SPSS Inc; 2010.
53. Kendler KS, Neale MC, Kessler RC, et al. The lifetime history of major depression in women: reliability of diagnosis and heritability. Arch Gen Psychiatry. 1993;50(11):863-870. (Pubitemid 23330978)
54. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499-507. (Pubitemid 43200344)
55. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci. 2001;26(11):44-48. (Pubitemid 32185179)
56. Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry. 2004;49(11):726-735. (Pubitemid 40100521)
57. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009;114(3):703-713.
58. Einarson A. Studying the safety of drugs in pregnancy: and the gold standard isI? J Clin Pharmacol Pharmacoepidemiol. 2010;1(1):3-8.
59. Briggs GG, Polifka J, the Research Committee, Organization of Teratology Information Specialists. Better data needed from pregnancy registries. Birth Defects Res A Clin Mol Teratol. 2009;85(2):109-111.
60. Kubon C, Sivertsen A, Vindenes H, et al. Completeness of registration of oral clefts in a medical birth registry: a population-based study. Acta Obstet Gynecol Scand. 2007;86(12):1453-1457. (Pubitemid 350135585)
61. Melve K, Lie R, Skjrven R, et al. Registration of Down syndrome in the Medical Birth Registry of Norway: validity and time trends. Acta Obstet Gynecol Scand. 2008;87(8):824-830.
62. Nilsen RM, Vollset, SM, Gjessing HK, et al. Self-selection and bias in a large prospective pregnancy cohort in Norway. Paediatr Perinat Epidemiol. 2009;23(6):597-608.
63. Robins LN, Wing JK, Wittchen HU, et al. The Composite International Diagnostic Interview. In: Mezzich J, Jorge M, Salloum I, eds. Psychiatric Epidemiology. Assessments Concepts and Methods. Baltimore, MD: The Johns Hopkins University; 1994.
64. Robins LN, Wing JK, Wittchen HU, et al. The Composite International Diagnostic Interview. Arch Gen Psychiatry. 1988;45(12):1069-1077.